BR0009644A - Tratamento de carcinoma de célula renal - Google Patents

Tratamento de carcinoma de célula renal

Info

Publication number
BR0009644A
BR0009644A BR0009644-0A BR0009644A BR0009644A BR 0009644 A BR0009644 A BR 0009644A BR 0009644 A BR0009644 A BR 0009644A BR 0009644 A BR0009644 A BR 0009644A
Authority
BR
Brazil
Prior art keywords
treatment
cell carcinoma
renal cell
effective amount
therapeutically effective
Prior art date
Application number
BR0009644-0A
Other languages
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0009644A publication Critical patent/BR0009644A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: "TRATAMENTO DE CARCINOMA DE CéLULA RENAL". A invenção refere-se a métodos para tratamento de pacientes nativos no tratamento assim como experimentados com tratamento, tendo RCC, para obter pelo menos uma resposta de tumor parcial envolvendo a administração de uma quantidade terapeuticamente efetiva de interferon alfa peguilado, por exemplo, interferon alfa 2b peguilado como monoterapia ou em associação com uma quantidade terapeuticamente efetiva de IL-2 são descritos.
BR0009644-0A 1999-04-08 2000-04-06 Tratamento de carcinoma de célula renal BR0009644A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
PCT/US2000/009127 WO2000061174A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha for renal cell carcinoma treatment

Publications (1)

Publication Number Publication Date
BR0009644A true BR0009644A (pt) 2002-01-08

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009644-0A BR0009644A (pt) 1999-04-08 2000-04-06 Tratamento de carcinoma de célula renal

Country Status (24)

Country Link
EP (2) EP1535623B1 (pt)
JP (2) JP3712914B2 (pt)
CN (1) CN1367702A (pt)
AR (1) AR029160A1 (pt)
AT (2) ATE296638T1 (pt)
AU (2) AU777406B2 (pt)
BR (1) BR0009644A (pt)
CA (1) CA2303752A1 (pt)
CO (1) CO5170412A1 (pt)
CY (1) CY1108919T1 (pt)
DE (2) DE60020442T2 (pt)
DK (2) DK1043025T3 (pt)
ES (2) ES2319777T3 (pt)
HK (2) HK1032533A1 (pt)
HU (1) HU230271B1 (pt)
MX (1) MXPA00003401A (pt)
MY (1) MY155221A (pt)
NO (1) NO328983B1 (pt)
NZ (1) NZ514629A (pt)
PE (1) PE20010026A1 (pt)
PT (2) PT1535623E (pt)
TW (2) TW200526243A (pt)
WO (1) WO2000061174A2 (pt)
ZA (1) ZA200108169B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére

Also Published As

Publication number Publication date
TWI310314B (en) 2009-06-01
DK1535623T3 (da) 2009-04-27
HUP0200781A3 (en) 2002-09-30
ES2319777T3 (es) 2009-05-12
PT1043025E (pt) 2005-09-30
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
WO2000061174A2 (en) 2000-10-19
ATE419002T1 (de) 2009-01-15
AR029160A1 (es) 2003-06-18
DE60041291D1 (de) 2009-02-12
DK1043025T3 (da) 2005-07-04
CY1108919T1 (el) 2014-07-02
HUP0200781A2 (en) 2002-08-28
EP1535623A1 (en) 2005-06-01
HK1075417A1 (en) 2005-12-16
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1043025B1 (en) 2005-06-01
ES2239953T3 (es) 2005-10-16
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
CN1367702A (zh) 2002-09-04
DE60020442D1 (de) 2005-07-07
PT1535623E (pt) 2009-03-19
DE60020442T2 (de) 2006-05-04
AU777406B2 (en) 2004-10-14
AU2004242454B2 (en) 2007-02-15
AU2004242454A1 (en) 2005-01-20
JP2000319196A (ja) 2000-11-21
HK1032533A1 (en) 2001-07-27
NO328983B1 (no) 2010-07-05
MY155221A (en) 2015-09-30
NO20014851L (no) 2001-12-07
ZA200108169B (en) 2003-01-06
NZ514629A (en) 2004-02-27
PE20010026A1 (es) 2001-02-05
CA2303752A1 (en) 2000-10-08
ATE296638T1 (de) 2005-06-15
JP2001288110A (ja) 2001-10-16
JP3712914B2 (ja) 2005-11-02
AU4204400A (en) 2000-11-14
WO2000061174A3 (en) 2001-01-25
TW200526243A (en) 2005-08-16
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
CL2010000828A1 (es) Composicion farmaceutica que comprende un conjugado pegilado de interferon alfa y ribavirina, util en la preparacion de un medicamento para las infecciones de hepatitis c cronica.
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
CY1107533T1 (el) Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR0014155A (pt) Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
ATE232396T1 (de) Oxydiertes thymosin beta 4
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
MY127670A (en) Pegylated interferon alfa-ccr5 antagonists combination hiv therapy
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
DK1032379T3 (da) Præparat med azelainsyre
BR0009644A (pt) Tratamento de carcinoma de célula renal
DE69821498D1 (de) Verwendung von amifostin
WO2000004863A3 (en) Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
DK1107795T3 (da) Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis
DK462687A (da) Forbindelse til behandling af retrovirusinfektioner.
BR0305018A (pt) Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
BR0108997A (pt) Terapia imune adjuvante para hiv
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
DK1287832T3 (da) Anvendelse af antagonist af leukæmiinhiberende faktor
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.